By Gary Petersen | Posted - Dec 5th, 2019

 

 

 

 

Updated #ASH19 Myeloma GUIDE! 11 Myeloma Specialists Choose Their Favorite Topics

Image result for ASH 2019 Images orlando

Myeloma Crowd provides the final pre #ASH19 listing of the most relevant myeloma abstracts. The listing is intended to let the participants with an interest in myeloma to find and attend the most important oral presentations. In addition, anyone following ASH by way of the internet can click on the abstracts to see what is new and important in myeloma treatment, research, and care.    A total of 11 well known and respected myeloma specialists provided their top picks for #ASH19.   Dr. Mike Thompson put together a summary of all the lists provided last year and has been so kind as to do it again this year.  His summary graph follows the listing and provides an overview of which abstracts has a consensus of opinion.  Some have as many as 4 and 5 specialists who has chosen them. The pre ASH19 summary of the best of the best abstracts from the following doctors is included below:

  • Dr. Vincent Rajkumar (Mayo)
  • Dr. Saad Usmani (Levine Cancer Institute)
  • Dr. Michael Thompson (Aurora Health Care)
  • Dr. Brian Durie (IMF)
  • Dr. Daniel Auclair (MMRF)
  • Dr. Luciano Costa(UAB)
  • Dr. Sigurdur Kristinsson (University of Iceland)
  • Dr. Suzanne Lentzsch (Columbia University)
  • Dr. Ola Landgren (MSKCC)
  • Dr. Rafael Fonseca(Mayo)
  • Dr. Parameswaran Hari (Medical College of Wisconsin)

The myeloma specialists have chosen 34 oral abstracts from the more than 243 oral abstracts listed.  We have summarized them below with the Abstract number, the Oral Session in which it will be presented, the Presenter, the date and time, and the Location of the session.  This should provide participants with information they can use to make sure they see some of the most relevant presentations for myeloma at ASH 2019.   A final listing will be provided after ASH 19 has been completed, and everyone has seen the oral and poster presentations. 

Abstract 49 - First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR/Cas9 Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T cells) in Advanced Multiple Myeloma (MM) and Sarcoma
Presenter: Edward Stadtmauer
Session: 801. Gene Therapy and Transfer: Advancing CAR T Cells: New Biology and Therapeutic Applications
Saturday, December 7, 2019: 7:30 AM-9:00 AM
W414AB (Orange County Convention Center)

Presenter: Sikander Ailawadhi
Session: 905. Outcomes Research—Malignant Conditions (Lymphoid Disease): Gaining Ground for Older Adults with Hematologic Malignancies: From Geriatric Assessment to Improving Survival
Saturday, December 7, 2019: 7:30 AM-9:00 AM
Sunburst Room (W340) (Orange County Convention Center)

Abstract 136 - Optimal Dual-Targeted CAR Construct Simultaneously Targeting Bcma and GPRC5D Prevents Bcma-Escape Driven Relapse in Multiple Myeloma
Presenter: Carlos Fernandez de Larrea
Session: 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Modeling Cellular Immunity and Tumor Microenvironment in Multiple Myeloma
Saturday, December 7, 2019: 9:30 AM-11:00 AM
Valencia A (W415A) (Orange County Convention Center)

Abstract 141 - Selinexor, Pomalidomide, and Dexamethasone (SPd) in Patients with Relapsed or Refractory Multiple Myeloma
Result Type: Paper
Presenter: Christine Chen
Session: 653. Myeloma: Therapy, excluding Transplantation: New Approaches in the Treatment of Relapsed/Refractory Plasma Cell Discrasias
Saturday, December 7, 2019: 9:30 AM-11:00 AM
Hall E1 (Orange County Convention Center)

Abstract 142 - T(11;14) and High BCL2 Expression Are Predictive Biomarkers of Response to Venetoclax in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Biomarker Analyses from the Phase 3 Bellini Study
Presenter: Simon Harrison
Session: 653. Myeloma: Therapy, excluding Transplantation: New Approaches in the Treatment of Relapsed/Refractory Plasma Cell Discrasias
Saturday, December 7, 2019: 9:30 AM-11:00 AM
Hall E1 (Orange County Convention Center)

Abstract 143 - First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial
Presenter: Luciano Costa
Session: 653. Myeloma: Therapy, excluding Transplantation: New Approaches in the Treatment of Relapsed/Refractory Plasma Cell Discrasias
Saturday, December 7, 2019: 9:30 AM-11:00 AM
Hall E1 (Orange County Convention Center)

Abstract 259 - Tandem Autologous-Autologous Vs. Autologous-Allogeneic Transplantation for Newly Diagnosed Multiple Myeloma: Pooled Analysis of 1,338 Patients from Four Trials with Long-Term Follow up
Presenter: Luciano Costa
Session: 732. Clinical Allogeneic Transplantation: Results: Outcomes
Saturday, December 7, 2019: 2:00 PM-3:30 PM
W307 (Orange County Convention Center)

Abstract 383 - Outcomes in Multiple Myeloma Based on Comorbidities and Race
Presenter: Martin Schoen
Program: Oral and Poster Abstracts
Session: 903. Health Services Research—Malignant Conditions (Myeloid Disease): Cancer Care Delivery and Quality of Life in Myeloid Malignancies
Sunday, December 8, 2019: 7:30 AM-9:00 AM
W307 (Orange County Convention Center)

Abstract 423 - Racial and Socioeconomic Disparities in the Utilization of Autologous Stem Cell Transplant for Treatment of Multiple Myeloma in the Era of Novel Agents
Presenter: Victoria Vardell
Session: 905. Outcomes Research—Malignant Conditions (Lymphoid Disease): Mountains Conquered, Challenges Remain: Survivorship and Disparities in the Hematologic Malignancies
Sunday, December 8, 2019: 9:30 AM-11:00 AM
W314 (Orange County Convention Center)

Abstract 506 - Single-Cell Characterization of the Multiple Myeloma (MM) Immune Microenvironment Identifies CD27-Negative T Cells As Potential Source of Tumor-Reactive Lymphocytes
Presenter: Cirino Botta
Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Pathogenesis and Bone Marrow Microenvironment
Sunday, December 8, 2019: 4:30 PM-6:00 PM
Hall E2 (Orange County Convention Center)

Abstract 509 - The Pathogenesis of Multiple Myeloma (MM) Is Preceded By Mutated Lymphopoiesis and B Cell Oligoclonality That Persist in Patients with Negative Minimal Residual Disease (MRD)
Presenter: Sara Rodríguez
Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Pathogenesis and Bone Marrow Microenvironment
Sunday, December 8, 2019: 4:30 PM-6:00 PM
Hall E2 (Orange County Convention Center)

Abstract 572 - Mutations and Copy Number Gains of the BCL2 Family Members Mediate Resistance to Venetoclax in Multiple Myeloma (MM) Patients
Presenter: Paola Neri
Session: 651. Myeloma Biology and Pathophysiology, excluding Therapy: Myeloma Clonal Heterogeneity: Therapeutic and Prognostic Implications
Monday, December 9, 2019: 7:00 AM-8:30 AM
W224CDGH (Orange County Convention Center)

Abstract 577- Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)
Presenter: Deepu Madduri
Session: 653. Myeloma: Therapy, excluding Transplantation: Novelty in CAR T in Relapsed/Refractory Multiple Myeloma
Monday, December 9, 2019: 7:00 AM-8:30 AM
Hall D (Orange County Convention Center)

Abstract 579 - Long-Term Follow-up of a Phase 1, First-in-Human Open-Label Study of LCAR-B38M, a Structurally Differentiated Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting B-Cell Maturation Antigen (BCMA), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
Presenter: Bai-Yan Wang
Session: 653. Myeloma: Therapy, excluding Transplantation: Novelty in CAR T in Relapsed/Refractory Multiple Myeloma
Monday, December 9, 2019: 7:00 AM-8:30 AM
Hall D (Orange County Convention Center)

Abstract 581 - Qip-Mass Spectrometry in High Risk Smoldering Multiple Myeloma Patients Included in the GEM-CESAR Trial: Comparison with Conventional and Minimal Residual Disease IMWG Response Assessment
Presenter: Noemi Puig
Session: 653. Myeloma: Therapy, excluding Transplantation: Novelty in CAR T in Relapsed/Refractory Multiple Myeloma
Monday, December 9, 2019: 7:00 AM-8:30 AM
Hall D (Orange County Convention Center)

Abstract 582 - Efficacy and Safety of Fully Human Bcma Targeting CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma
Presenter: Chunrui Li
Session: 653. Myeloma: Therapy, excluding Transplantation: Novelty in CAR T in Relapsed/Refractory Multiple Myeloma
Monday, December 9, 2019: 7:00 AM-8:30 AM
Hall D (Orange County Convention Center)

Abstract 604 - Outcomes of Transplant-Eligible Newly Diagnosed Ultra-High Risk Myeloma Patients Treated in the NCRI Myeloma XI Trial Indicate the Need for Early Treatment Stratification and Novel Treatment Approaches
Presenter: Martin Kaiser
Session: 731. Clinical Autologous Transplantation: Results: Multiple Myeloma: Results from Prospective Clinical Trials
Monday, December 9, 2019: 7:00 AM-8:30 AM
Sunburst Room (W340) (Orange County Convention Center)

Abstract 691 -  Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Griffin Study Update
Number: 691
Presenter: Peter Voorhees
Session: 653. Myeloma: Therapy, excluding Transplantation: Therapeutics Questions in Newly Diagnosed Myeloma
Monday, December 9, 2019: 10:30 AM-12:00 PM
Hall E1 (Orange County Convention Center)

Abstract 692 - Evaluation of the Prognostic Value of Positron Emission Tomography-Computed Tomography (PET-CT) at Diagnosis and Follow-up in Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients Treated in the Phase 3 Cassiopeia Study: Results of the Cassiopet Companion Study
Presenter: Philippe Moreau
Session: 653. Myeloma: Therapy, excluding Transplantation: Therapeutics Questions in Newly Diagnosed Myeloma
Monday, December 9, 2019: 10:30 AM-12:00 PM
Hall E1 (Orange County Convention Center)

Abstract 693 - Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the First Interim Analysis of the Phase 2 EMN12/HOVON129 Study
Presenter: Niels Van De Donk
Session: 653. Myeloma: Therapy, excluding Transplantation: Therapeutics Questions in Newly Diagnosed Myeloma
Monday, December 9, 2019: 10:30 AM-12:00 PM
Hall E1 (Orange County Convention Center)


Abstract 694 - Randomized Trial of Lenalidomide and Dexamethasone Versus Clarythromycin, Lenalidomide and Dexamethasone As First Line Treatment in Patients with Multiple Myeloma Not Candidates for Autologous Stem Cell Transplantation: Results of the GEM-Claridex Clinical Trial
Presenter: Noemi Puig
Session: 653. Myeloma: Therapy, excluding Transplantation: Therapeutics Questions in Newly Diagnosed Myeloma
Time and Location:
Monday, December 9, 2019: 10:30 AM-12:00 PM
Hall E1 (Orange County Convention Center)

Abstract 781 - Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd
Presenter: Maria-Victoria Mateos
Session: 731. Clinical Autologous Transplantation: Results: Autologous Stem Cell Transplantation: Lymphoma and Plasma Cell Disorders
Monday, December 9, 2019: 2:45 PM-4:15 PM
W311ABCD (Orange County Convention Center)


Abstract 695 - Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (Ixa Dara dex) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; Results of the Interim Efficacy Analysis of the Phase II HOVON 143 Study
Presenter: Claudia Stege
Session: 653. Myeloma: Therapy, excluding Transplantation: Therapeutics Questions in Newly Diagnosed Myeloma
Monday, December 9, 2019: 10:30 AM-12:00 PM
Hall E1 (Orange County Convention Center)

Abstract 859 - Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Overall Survival in Alcyone
Presenter: Maria-Victoria Mateos
Session: 653. Myeloma: Therapy, excluding Transplantation: Improving the Outcomes of Newly Diagnosed Multiple Myeloma
Monday, December 9, 2019: 4:30 PM-6:00 PM
Hall E2 (Orange County Convention Center)

Abstract 860 - Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Disease (MRD)-Based Dara-Krd Consolidation in Patients with Newly Diagnosed Multiple Myeloma (NDMM)
Presenter: Luciano Costa
Session: 653. Myeloma: Therapy, excluding Transplantation: Improving the Outcomes of Newly Diagnosed Multiple Myeloma
Monday, December 9, 2019: 4:30 PM-6:00 PM
Hall E2 (Orange County Convention Center)

Abstract 862 - Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple Myeloma: A Clinical and Correlative Phase 2 Study
Presenter: Ola Landgren
Session: 653. Myeloma: Therapy, excluding Transplantation: Improving the Outcomes of Newly Diagnosed Multiple Myeloma
Monday, December 9, 2019: 4:30 PM-6:00 PM
Hall E2 (Orange County Convention Center)


Abstract 863 - Daratumumab (DARA) Maintenance Therapy Improves Depth of Response and Results in Durable Progression-Free Survival (PFS) Following Dara Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) Induction Therapy in Multiple Myeloma (MM): Update of the Lyra Study
Presenter: Robert Rifkin
Session: 653. Myeloma: Therapy, excluding Transplantation: Improving the Outcomes of Newly Diagnosed Multiple Myeloma
Monday, December 9, 2019: 4:30 PM-6:00 PM
Hall E2 (Orange County Convention Center)

Abstract 864 - Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma
Presenter: Prashant Kapoor
Session: 653. Myeloma: Therapy, excluding Transplantation: Improving the Outcomes of Newly Diagnosed Multiple Myeloma
Monday, December 9, 2019: 4:30 PM-6:00 PM
Hall E2 (Orange County Convention Center)

Abstract 925 - First Analysis from a Phase 1/2 Study of Venetoclax in Combination with Daratumumab and Dexamethasone, +/- Bortezomib, in Patients with Relapsed/Refractory Multiple Myeloma
Presenter: Nizar Bahlis
Session: 653. Myeloma: Therapy, excluding Transplantation: Novel Therapy for Relapsed Myeloma
Monday, December 9, 2019: 6:15 PM-7:45 PM
Valencia A (W415A) (Orange County Convention Center)

Abstract 926 - Phase I/II Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Dexamethasone As Targeted Therapy for Patients with t(11;14) Relapsed/Refractory Multiple Myeloma
Presenter: Jonathan Kaufman
Session: 653. Myeloma: Therapy, excluding Transplantation: Novel Therapy for Relapsed Myeloma
Monday, December 9, 2019: 6:15 PM-7:45 PM
Valencia A (W415A) (Orange County Convention Center)

Abstract 927 - Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy
Presenter: Jesus Berdeja
Session: 653. Myeloma: Therapy, excluding Transplantation: Novel Therapy for Relapsed Myeloma
Monday, December 9, 2019: 6:15 PM-7:45 PM
Valencia A (W415A) (Orange County Convention Center)

Abstract 928 - Translational Analysis from CARTITUDE-1, an Ongoing Phase 1b/2 Study of JNJ-4528 BCMA-targeted CAR-T Cell Therapy in Relapsed and/or Refractory Multiple Myeloma (R/R MM), Indicates Preferential Expansion of CD8+ T Cell Central Memory Cell Subset
Presenter: Enrique Zudaire
Session: 653. Myeloma: Therapy, excluding Transplantation: Novel Therapy for Relapsed Myeloma
Monday, December 9, 2019: 6:15 PM-7:45 PM
Valencia A (W415A) (Orange County Convention Center)

Abstract 930 - A Bispecific CAR-T Cell Therapy Targeting Bcma and CD38 for Relapsed/Refractory Multiple Myeloma: Updated Results from a Phase 1 Dose-Climbing Trial
Presenter: Heng Mei
Session: 653. Myeloma: Therapy, excluding Transplantation: Novel Therapy for Relapsed Myeloma
Monday, December 9, 2019: 6:15 PM-7:45 PM
Valencia A (W415A) (Orange County Convention Center)

LBA-6 - Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)
Presenter: Saad Usmani
Program: General Sessions
Session: Late-Breaking Abstracts Session
Tuesday, December 10, 2019: 7:30 AM-9:00 AM
Hall D (Orange County Convention Center)

 

Dr. Michael Thomson's Summary Graph.  Thank You doctor for your help in providing this ASH summary!

Image

 

 
Gary Petersen
About the Author

Gary Petersen - Gary is a myeloma survivor and patient advocate. His work centers around helping patients live longer by helping them to find facilities who are beating the average survival statistics. You can find Gary's site at www.myelomasurvival.com and follow him on Twitter at @grpetersen1

ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
 

Add a Comment

 

MORE MYELOMA CROWD NEWS

Thanks to our site sponsors:

.